Mindmed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC.
Benefits of LSD
LSD is a psychoactive drug that can have profound effects on the mind. It has many benefits, including its ability to treat anxiety disorders.
It can also be used to treat depression and mood swings. It can also help people who have addictions, such as alcoholism or cigarette smoking.
A person who takes LSD may feel euphoria, bliss, peace, dreaminess, and a sense of transcendence. They may also experience accelerated thoughts and unusual insight.
The psychedelic effects of LSD are referred to as a “trip.” It can last anywhere from 12 hours to a day or more, depending on the dosage.
The physical side effects of LSD include numbness, increased heart rate and blood pressure, reduced co-ordination, nausea and tremors. The drug also affects the brain with visual distortions and sensory hallucinations.
Benefits of MM-120
MindMed is a psychedelic medicine biotech company focused on the discovery, development and deployment of psychedelic-inspired medicines to address addiction and mental illness. Its drug development pipeline comprises psilocybin, LSD, MDMA, DMT and 18-MC.
MM-120, the company’s lead program, is a pharmacologically optimized form of lysergic acid diethylamide (LSD). The drug is being developed to treat generalized anxiety disorder and other brain-based disorders.
MM-120 recently received clearance from the Food and Drug Administration to proceed with a Phase 2b dose-optimization trial for GAD. The trial is a multi-centre, parallel, double-blind, placebo-controlled, and randomized clinical trial that will evaluate the decline in anxiety symptoms after a single dose of MM-120. The trial will also evaluate safety, tolerability, and quality of life up to 12 weeks following dosing.
Benefits of MM-140
Mind Medicine (NASDAQ: MNMD), a clinical-stage psychedelic medicine biotech company, is assembling a robust pipeline of innovative products that target addiction and mental illness. The company’s flagship drug candidate is MM-120, a pharmaceutically optimized form of the euphoria-inducing LSD D-Tartrate. This patented and patent-protected product has been shown to be a potent, long-lasting and non-narcotic painkiller, but its benefits go far beyond that.
It also has a broad research partnership with UHB involving exclusive worldwide rights to data, compounds and patents associated with UHB’s LSD research. The company’s patent strategy includes pursuing protection for compositions of matter, methods of treatment and diagnostic devices and analytics related to psychedelics. In addition, it is attempting to reverse engineer the pharmacology of a number of the more common psychedelics. Finally, it has a number of upcoming studies in its arsenal including a multi-center randomized placebo controlled trial of MM-120 in the treatment of Generalized Anxiety Disorder. Its stock is crushing it today, as shares surged 45.4%, oh, and it complies with Nasdaq’s minimum share price requirement.
Benefits of MM-160
MM-160 has been developed by mindmed as a pharmaceutically optimized form of LSD for the treatment of GAD. The compound has been shown to significantly reduce symptoms of anxiety in patients with the condition. It also has been found to have a number of other benefits including an increase in motivation and focus, improved cognitive performance and enhanced social interactions.
Regardless of whether you’re looking to buy or sell a stock, it’s important to understand the stock’s ranking. InvestorsObserver rates stocks based on an Overall score, which is a combination of technical and fundamental factors. A stock with a high Overall score is likely to be more attractive to investors than a stock with a low Overall score.
Mind Medicine (MindMed) Inc has an Overall score of 62, which places it around the top of the Biotechnology industry. It also ranks better than 77 percent of all stocks in this industry. For more information, check out our full MNMD stock report.